
Isomorphic Labs raises $5 billion Series C for AI drug discovery
The AMW Read
The $5 billion round materially updates a known AI drug discovery company and signals a major capital commitment to the sector.
Isomorphic Labs raises $5 billion Series C for AI drug discovery
Isomorphic Labs has raised $5 billion in an oversubscribed Series C round co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, while Alphabet increased its investment. The London-based company plans to improve its IsoDDE drug design engine, expand its internal and partnered drug candidate pipeline, and build AI-driven bioengineering infrastructure.
The round puts substantial capital behind a model-based approach to drug discovery. IsoDDE combines simulation models across therapeutic areas and drug types, while the company also uses proprietary agents to explore biological systems. Isomorphic Labs says its internal oncology and immunology programs, along with partnered projects, have produced positive preclinical results. Those results remain distinct from evidence generated in human trials.
For investors, the next concrete measure is whether the reported preclinical progress leads to clinical trials across the company's own and partnered programs. For drug developers, the financing supports further work on both molecule design and the infrastructure needed to advance candidates. The round also follows an October report that Isomorphic Labs was discussing funding at a valuation of at least $40 billion; the current report does not state the valuation achieved.